
    
      Subjects will be randomised in a 1:1 ratio to receive either SB11 or Lucentis® (administered
      via intravitreal (ITV) 0.5 mg every 4 weeks). Investigational Products (IP) (SB11 or
      Lucentis®) will be administered up to Week 48, and the last assessment will be done at Week
      52.
    
  